Study Evaluating the Safety and Efficacy of Itacitinib in Participants With Bronchiolitis Obliterans Syndrome Following Lung Transplantation

Study Evaluating the Safety and Efficacy of Itacitinib in Participants With Bronchiolitis Obliterans Syndrome Following Lung Transplantation
Recruiting
99 years or below
All
Phase 1
6 participants needed
1 Location

Brief description of study

You are being invited to participate in a research study because you have Bronchiolitis Obliterans Syndrome. Bronchiolitis Obliterans Syndrome (BOS) is a long term (chronic) rejection process that can occur in the transplanted lungs.  Itacitinib works by blocking your body from producing substances called cytokines. Cytokines can cause inflammation that may contribute to your BOS. This is an open-label Study, which means that both you and your Study Doctor will know what Study Drug you are receiving.
 
The Study has 2 phases, or parts.  The Study Doctor will tell you whether you will be in Phase 1 or Phase 2 of the Study, and which cohort (treatment group) you might be in if you are in Phase 1.
 

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Bronchiolitis Obliterans Syndrome
  • Age: 99 years or below
  • Gender: All


Updated on 04 Aug 2024. Study ID: 834433

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center